Miransertib - ArQule

Drug Profile

Miransertib - ArQule

Alternative Names: ARQ-092; Miransertib

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ArQule; Daiichi Sankyo Company
  • Developer ArQule; National Human Genome Research Institute
  • Class Antineoplastics; Cyclobutanes; Imidazoles; Pyridines; Small molecules
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Proteus syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Growth disorders; Proteus syndrome
  • Phase I Solid tumours
  • Preclinical Congenital heart defects; Sickle cell anaemia

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease) in USA (PO)
  • 03 Apr 2018 ArQule, in collaboration with NIH, plans a registrational trial for Proteus syndrome in 2018
  • 20 Nov 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top